New evidence suggests that the combined oral contraceptive Yasmin (drospirenone + ethinylestradiol) may be associated with a slightly higher risk of venous thromboembolism (VTE) than previously thought. Although firm conclusions cannot yet be drawn, the likelihood of this rare adverse event in women taking Yasmin is now thought to lie somewhere between that for levonorgestrel-containing pills and that for desogestrel or gestodene-containing pills.
When used appropriately, the benefits of combined oral contraceptives far outweigh the risk of VTE. However, prescribers should consider the new findings during contraceptive consultations and should exercise caution when prescribing Yasmin or any other combined oral contraceptive to women with risk factors for VTE (eg BMI >30kg/m2).
Further information: MHRA Drug Safety Update